Project description:Lecanicillium fungicola, the causative agent of dry bubble disease on Agaricus bisporus results in significant crop losses for mushroom growers worldwide. Dry bubble disease is treated through strict hygiene control methods and the application of chemical fungicides but an increase in fungicide resistant L. fungicola strains has resulted in a need to develop alternative biocontrol treatment methods. The aim of the work presented here was to evaluate the response of L. fungicola to a Bacillus velezensis isolate to assess its potential as a novel biocontrol agent. The bacterial species in Serenade, a commercially available biocontrol treatment was also included in this analysis. Exposure of 48 hr L. fungicola cultures to 25% v/v 96h B. velezensis culture filtrate resulted in a 45% reduction in biomass (P < 0.0002) and a disruption in hyphal structure and morphology. Characterisation of the proteomic response of L. fungicola following exposure to B. velezensis culture filtrate revealed an increase in the abundance of a variety of proteins associated with stress response (Norsolorinic acid reductase (+8 fold), isocitrate lyase (+7 fold) and MMS19 nucleotide excision repair protein (+4 fold). There was also a decrease in the abundance of proteins associated with transcription (40S ribosomal protein S30 (-33 fold), 60S ribosomal protein L5 (-45 foldThe results presented here indicate that B. velezensis culture filtrate is capable of inhibiting the growth of L. fungicola and inducing a stress response, thus indicating its potential to control this important pathogen of mushrooms.
Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
